Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions
The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Boston Scientific will acquire SoniVie for up to $600 million on 100% basis, adding the TIVUS ultrasound system to its hypertension treatment pipeline. Deal closes in H1 2025.
Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc., The Progressive Corp. and Boston Scientific Corp., as well as micro-cap stock Cooper-Standard Holdings Inc..
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
CS Diagnostics Corp. (OTCQB: CSDX), a medical technology innovator , continues to advance cancer treatment technology with CS Protect-Hydrogel , a groundbreaking tissue spacer that enhances radiation therapy by protecting healthy tissue. Alongside this milestone, the company has also launched MEDUSA , a next-generation smart disinfectant designed to revolutionize hygiene standards across industries.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSEBSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Medical technology company Becton, Dickinson and Company (NYSEBDX)
will be announcing earnings results tomorrow before market open. Here’s what to look for.
Medical device company Boston Scientific (NYSEBSX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 22.4% year on year to $4.56 billion. Guidance for next quarter’s revenue was optimistic at $4.55 billion at the midpoint, 2.5% above analysts’ estimates. Its non-GAAP profit of $0.70 per share was 6.6% above analysts’ consensus estimates.
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.
